New hope for leukemia patients: trial tests Chemo-Free treatment
NCT ID NCT04747912
Summary
This study is testing whether adding a targeted drug called inotuzumab ozogamicin to standard treatment can help adults with a specific, newly diagnosed type of acute lymphoblastic leukemia (Ph+ ALL) achieve a deep remission faster. The goal is to see if this approach leads to better disease control by making the cancer undetectable with sensitive tests. The trial is for adults who have not yet received treatment for this leukemia.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University of Chicago Medical Center
Chicago, Illinois, 60615, United States
Conditions
Explore the condition pages connected to this study.